Drugs.com - Monthly Update October 2025 скачать в хорошем качестве

Drugs.com - Monthly Update October 2025

This month’s update dives into significant FDA approvals affecting key therapeutic areas. Discover groundbreaking treatments like Novo Nordisk’s Rybelsus for cardiovascular risk reduction in diabetes, and innovative solutions like Gazyva for lupus nephritis. Tune in to learn how these advancements could impact patient management and outcomes. Rybelsus (semaglutide): Exploring its new role in cardiovascular risk reduction for adults with type 2 diabetes. https://www.drugs.com/rybelsus.html Zoryve (roflumilast): A breakthrough steroid-free topical treatment for eczema in young children. https://www.drugs.com/zoryve.html Gazyva (obinutuzumab): Approved for lupus nephritis, offering new hope for managing this serious kidney ailment. https://www.drugs.com/gazyva.html Lynkuet (elinzanetant): A hormone-free option for alleviating hot flashes due to menopause. https://www.drugs.com/lynkuet.html Lasix ONYU (furosemide injection): Introducing an at-home infusion method for heart failure patients dealing with edema. https://www.drugs.com/pro/lasix-onyu.... Jascayd (nerandomilast): A new approval to combat the progression of idiopathic pulmonary fibrosis. https://www.drugs.com/pro/jascayd.html Chapters: 00:00 - Intro 00:40 - Rybelsus 01:36 - Zoryve Cream 02:17 - Gazyva 02:51 - Lynkuet 03:01 - Lasix ONYU 03:44 - Jascayd 04:16 - Outro Follow Drugs.com: X   / drugscom   Facebook   / drugscom   Signup to our newsletters https://www.drugs.com/newsletters/ Download the app https://www.drugs.com/apps/